BR112013017875A2 - introdução corneana de agentes de ligação cruzada por iontoforese para o tratamento de ceratocone e composições oftálmicas relacionadas - Google Patents

introdução corneana de agentes de ligação cruzada por iontoforese para o tratamento de ceratocone e composições oftálmicas relacionadas

Info

Publication number
BR112013017875A2
BR112013017875A2 BR112013017875A BR112013017875A BR112013017875A2 BR 112013017875 A2 BR112013017875 A2 BR 112013017875A2 BR 112013017875 A BR112013017875 A BR 112013017875A BR 112013017875 A BR112013017875 A BR 112013017875A BR 112013017875 A2 BR112013017875 A2 BR 112013017875A2
Authority
BR
Brazil
Prior art keywords
corneal
iontophoresis
treatment
keratoconus
ophthalmic compositions
Prior art date
Application number
BR112013017875A
Other languages
English (en)
Other versions
BR112013017875B1 (pt
Inventor
Edoardo Stagni
Fulvio Foschini
Giovanni Cavallo
Giulio Luciani
Pierre Roy
Original Assignee
Sooft Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sooft Italia Spa filed Critical Sooft Italia Spa
Publication of BR112013017875A2 publication Critical patent/BR112013017875A2/pt
Publication of BR112013017875B1 publication Critical patent/BR112013017875B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

introdução corneana de agentes de ligação cruzada por iontoforese para o tratamento de ceratocone e composições oftálmicas relacionadas a presente invenção se refere à utilização de iontoforese para introduzir composições oftálmicas (em particular, colírios) preferivelmente contendo riboflavina, ou outros agentes de ligação cruzada, projetas para embeber o estroma corneano na prática da ligação cruzada de colágeno corneano (cxl) para o tratamento de ceratocone, e também se refere às composições oftálmicas correspondentes adaptadas para serem administradas por iontoforese no tratammento de ceratocone por ligação cruzada de colágeno corneano; de acordo com a invenção, é fornecida uma composição oftálmica para o tratamento de ceratocone por iontoforese corneana caracterizada pelo fato de compreender agentes de ligação cruzada possuindo propriedades tamponantes e cujo valor de ph inicial esteja entre 5, e 6, e/ou biointensificadores, e/ou fotointensificadores.
BR112013017875-2A 2011-01-12 2011-01-12 Composição oftálmica BR112013017875B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2011/000010 WO2012095877A1 (en) 2011-01-12 2011-01-12 Corneal delivery of cross-linking agents by iontophoresis for the treatment of keratoconus and related ophthalmic compositions

Publications (2)

Publication Number Publication Date
BR112013017875A2 true BR112013017875A2 (pt) 2016-10-11
BR112013017875B1 BR112013017875B1 (pt) 2021-06-29

Family

ID=44544243

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013017875-2A BR112013017875B1 (pt) 2011-01-12 2011-01-12 Composição oftálmica

Country Status (9)

Country Link
US (1) US20130310732A1 (pt)
EP (1) EP2663281B1 (pt)
JP (1) JP2014503552A (pt)
CN (1) CN103384514A (pt)
BR (1) BR112013017875B1 (pt)
ES (1) ES2590127T3 (pt)
IL (1) IL227412A (pt)
MX (1) MX2013008042A (pt)
WO (1) WO2012095877A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6377906B2 (ja) 2010-03-19 2018-08-22 アヴェドロ・インコーポレーテッドＡｖｅｄｒｏ，Ｉｎｃ． 眼治療を適用およびモニターするためのシステム
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
JP6122845B2 (ja) 2011-06-02 2017-04-26 アヴェドロ・インコーポレーテッドＡｖｅｄｒｏ，Ｉｎｃ． 時間ベースの光活性剤の送達又は光活性マーカの存在をモニターするシステム及び方法
WO2013028833A1 (en) 2011-08-23 2013-02-28 Anthony Natale Systems and methods for treating pathogenic infection
US9023092B2 (en) 2011-08-23 2015-05-05 Anthony Natale Endoscopes enhanced with pathogenic treatment
WO2013148896A1 (en) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular treatment solutions, delivery devices and delivery augmentation methods
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
ITRM20130248A1 (it) * 2013-04-24 2014-10-25 Medivis S R L Formulazioni di riboflavina per il cross-linking transepiteliale.
US9931199B2 (en) * 2014-05-05 2018-04-03 Roberto Gustavo ALBERTAZZI Methods and apparatus for treating keratoconus
EP3212140B1 (en) 2014-10-27 2021-12-01 Avedro, Inc. Systems for cross-linking treatments of an eye
WO2016077747A1 (en) 2014-11-13 2016-05-19 Avedro, Inc. Multipass virtually imaged phased array etalon
EP4082547A1 (en) * 2014-12-02 2022-11-02 Avedro, INC. Systems, methods, and compositions for cross-linking treatments of an eye
EP3233174B1 (en) 2014-12-19 2021-03-31 Kemin Industries, Inc. Intraocular delivery of bioactive molecules using iontophoresis
EP3285704B1 (en) 2015-04-24 2020-11-18 Avedro Inc. Systems for photoactivating a photosensitizer applied to an eye
WO2016191342A1 (en) 2015-05-22 2016-12-01 Avedro, Inc. Systems and methods for monitoring cross-linking activity for corneal treatments
CN108025011A (zh) * 2015-07-21 2018-05-11 艾维德洛公司 用光敏剂治疗眼睛的系统和方法
WO2017139102A1 (en) 2016-02-11 2017-08-17 Lifecell Corporation Methods for stabilizing collagen-containing tissue products against enzymatic degradation
WO2017180851A1 (en) 2016-04-13 2017-10-19 Avedro, Inc. Systems and methods for delivering drugs to an eye
KR20210134636A (ko) * 2019-01-25 2021-11-10 아베드로, 인코포레이티드 눈 치료용 화합물 및 조성물
IT201900011985A1 (it) 2019-07-17 2021-01-17 Vision Eng Italy Srl Formulazione liquida, in particolare per trattare un tessuto corneale
CN114848830A (zh) * 2022-04-26 2022-08-05 复旦大学附属眼耳鼻喉科医院 一种用于提高角膜交联效果的制剂及角膜交联组合制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU758862B2 (en) * 1998-03-09 2003-04-03 Ista Pharmaceuticals, Inc Use of corneal hardening agents in enzyme orthokeratology
CA2399414A1 (en) 2000-02-11 2001-08-16 The General Hospital Corporation Photochemical tissue bonding
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US20030023228A1 (en) * 2001-07-20 2003-01-30 Parkinson Thomas M. Ocular iontophoretic device and method for using the same
EP1933941A2 (en) * 2005-08-25 2008-06-25 Philip R. Houle Treatment systems for delivery of sensitizer solutions
US20080015660A1 (en) 2006-07-13 2008-01-17 Priavision, Inc. Method And Apparatus For Photo-Chemical Oculoplasty/Keratoplasty
ITRM20070356A1 (it) * 2007-06-26 2008-12-27 Sooft Italia Srl Soluzione oculare sterile monouso e suo procedimento di produzione per il cross linking corneale del cheratocono
EP2025332A1 (fr) 2007-08-13 2009-02-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Composition thérapeutique aromatisée à base d'argile
US20090149923A1 (en) 2007-12-07 2009-06-11 21X Corporation Dba Priavision, Inc. Method for equi-dosed time fractionated pulsed uva irradiation of collagen/riboflavin mixtures for ocular structural augmentation
US20090306579A1 (en) * 2008-02-25 2009-12-10 Eyegate Pharmaceuticals, Inc. Delivery of corticosteroids through iontophoresis
US9913806B2 (en) * 2008-06-25 2018-03-13 Fe3 Medical, Inc. Patches and methods for the transdermal delivery of a therapeutically effective amount of iron
IT1393402B1 (it) * 2008-08-28 2012-04-20 Sooft Italia Spa Uso di enhancer eventualmente con riboflavina, nonche' relative composizioni oftalmiche per cross-linking corneale del cheratocono o di altre patologie ectasiche corneali
ES2679673T3 (es) * 2008-12-31 2018-08-30 Eyegate Pharmaceuticals, Inc. Sistema para iontoforesis ocular con amortiguación
ITRM20110560A1 (it) 2011-10-25 2013-04-26 Sooft Italia Spa Migliorata composizione di cross-linking per il trattamento del cheratocono mediante iontoforesi

Also Published As

Publication number Publication date
ES2590127T3 (es) 2016-11-18
JP2014503552A (ja) 2014-02-13
EP2663281A1 (en) 2013-11-20
IL227412A (en) 2017-02-28
US20130310732A1 (en) 2013-11-21
MX2013008042A (es) 2013-09-16
CN103384514A (zh) 2013-11-06
EP2663281B1 (en) 2016-08-10
BR112013017875B1 (pt) 2021-06-29
WO2012095877A1 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
BR112013017875A2 (pt) introdução corneana de agentes de ligação cruzada por iontoforese para o tratamento de ceratocone e composições oftálmicas relacionadas
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
EA201300272A1 (ru) Применение фотоусиливающих агентов в ассоциации с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы
BR112015021334A2 (pt) formulações oculares para entrega de droga ao segmento posterior do olho
BR112017015230A8 (pt) Método de determinação de um filtro para uma lente oftálmica e lente oftálmica compreendendo um filtro desta natureza
PH12019500423A1 (en) Pharmaceutical composition
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
NZ704247A (en) Compositions and treatment for eye diseases and disorders
BR112014005700A2 (pt) composições oftálmicas compreendendo derivados de prostaglandina f2 alfa e ácido hialurônico
BR112015019039A8 (pt) compostos antagonistas de integrina fluorados, composição farmacêutica compreendendo ditos compostos e uso destes para tratar ou prevenir uma doença ou condição mediada por uma av integrina
BR112016021034A8 (pt) composição farmacêutica, uso da mesma e kit
BR112018072343A2 (pt) método de determinação de um filtro para uma lente oftálmica em função de uma grandeza representativa de uma sensibilidade dinâmica do olho de um portador a uma variação de um fluxo luminoso
BR112014027047A2 (pt) nova formulação
MX355853B (es) Composicion oftalmica para el tratamiento de infeccion ocular.
CY1124538T1 (el) Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης
MX342930B (es) Composicion reticuladora mejorada, suministrada por iontoforesis, util para el tratamiento de queratocono.
BR112015004469A2 (pt) sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares
EA035539B9 (ru) Офтальмологическая композиция для применения при лечении офтальмологических расстройств, связанных с изменениями роговично-конъюнктивальной поверхности
ZA202003944B (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
PH12015501555A1 (en) Topical aqueous ophthalmic compositions containing a 1h-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
BR112017014379A2 (pt) composição para o tratamento de infecções causadas pelo acaro demodex spp
BR112018006474A2 (pt) nova composição oftalmológica compreendendo rebamipide e método para preparar o mesmo
BR112018007686A2 (pt) uso terapêutico de uma solução oftál¬mica aquosa es-teril
TW201613596A (en) Ophthalmic suspension preparation

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/01/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.